The Group’s strategy and business model are outlined in the Strategic Report of the ‘2025 Annual Report and Financial Statements’.
CelLBxHealth plc is a CTC intelligence company focused on the commercialisation of innovative CTC technologies for use in cancer research, diagnostics, drug development and clinical oncology. The Company’s patent-protected Parsortix® Platform enables the isolation and harvest of intact living cancer cells from a blood sample and can be integrated with existing laboratory instruments and workflows for downstream analysis, including whole-cell imaging, proteomic profiling and genomic testing.
Following a strategic review in 2025, CelLBxHealth has transitioned to a commercially focused, partner-led and capital-efficient business model. The revised strategy is centered on accelerating adoption of the Parsortix platform through integration with established downstream diagnostic platforms, laboratory workflows and molecular testing solutions, rather than pursuing a standalone development pathway.
The Company is developing strategic collaborations with leading diagnostics and life sciences organisations, including QIAGEN, Roche Diagnostics, Myriad Genetics and Illumina, to validate CTC-based workflows and support broader adoption across research institutions, clinical laboratories and contract research organizations (CROs).
CelLBxHealth’s vision is to improve outcomes for cancer patients through CTC testing by enabling repeatable, real-time cancer assessment from blood. We believe that CTC analysis can complement existing tissue, circulating tumor DNA (ctDNA) and (m)RNA gene expressions testing approaches and provide valuable insights into therapy selection, treatment monitoring and disease progression.
To support commercial growth, CelLBxHealth is focused on three core revenue streams:
- Product Sales
Commercialisation of the Parsortix platform and related consumables through partnerships with CROs, clinical laboratories, translational research centers and research institutions, supporting both independent cancer research and clinical workflow adoption. - Laboratory Services
Delivery of clinical trial support, assay development and translational research services from the Company’s GCLP-compliant UK laboratory facility, in collaboration with pharmaceutical, biotechnology and diagnostics partners. - Lab Developed Tests (LDTs)
Development and commercialisation of CTC-based laboratory-developed tests through a combination of strategic partnerships and targeted in-house development, leveraging established downstream analysis platforms and existing laboratory infrastructure.
The Company’s revised strategy emphasises partnership-driven growth, operational efficiency and disciplined capital allocation, with the objective of accelerating commercial adoption, generating sustainable revenue growth and delivering long-term shareholder value.
Corporate governance
AIM rule 50